[{"address1": "369 South San Antonio Road", "city": "Los Altos", "state": "CA", "zip": "94022", "country": "United States", "phone": "650 200 0412", "website": "https://www.altoneuroscience.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.", "fullTimeEmployees": 88, "companyOfficers": [{"maxAge": 1, "name": "Dr. Amit  Etkin M.D., Ph.D.", "age": 47, "title": "Founder, Chairman of the Board, CEO & President", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 705653, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nicholas C. Smith", "age": 35, "title": "CFO & Secretary", "yearBorn": 1989, "fiscalYear": 2023, "totalPay": 624125, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Savitz M.D., Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 579569, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dan  Segal B.Sc. (Hons), BCom, CA, MSc", "age": 62, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael C. Hanley M.B.A.", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin R. McQuade J.D.", "age": 49, "title": "General Counsel & Chief Administrative Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Powell", "age": 49, "title": "Chief Development Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.78, "open": 2.76, "dayLow": 2.67, "dayHigh": 2.817, "regularMarketPreviousClose": 2.78, "regularMarketOpen": 2.76, "regularMarketDayLow": 2.67, "regularMarketDayHigh": 2.817, "payoutRatio": 0.0, "forwardPE": -0.9756098, "volume": 286068, "regularMarketVolume": 286068, "averageVolume": 261633, "averageVolume10days": 207430, "averageDailyVolume10Day": 207430, "bid": 2.59, "ask": 2.8, "bidSize": 9, "askSize": 8, "marketCap": 75516560, "fiftyTwoWeekLow": 2.67, "fiftyTwoWeekHigh": 18.35, "fiftyDayAverage": 3.951, "twoHundredDayAverage": 8.69065, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -90696528, "profitMargins": 0.0, "floatShares": 19401530, "sharesOutstanding": 26970200, "sharesShort": 3984030, "sharesShortPriorMonth": 4054178, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.14770001, "heldPercentInsiders": 0.07509, "heldPercentInstitutions": 0.89709, "shortRatio": 16.42, "shortPercentOfFloat": 0.1875, "impliedSharesOutstanding": 26970200, "bookValue": 6.12, "priceToBook": 0.45751634, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -57447000, "trailingEps": -2.38, "forwardEps": -2.87, "enterpriseToEbitda": 1.441, "52WeekChange": -0.82304263, "SandP52WeekChange": 0.16050637, "quoteType": "EQUITY", "currentPrice": 2.8, "targetHighPrice": 18.0, "targetLowPrice": 4.0, "targetMeanPrice": 12.72333, "targetMedianPrice": 13.5, "recommendationMean": 1.28571, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 181700992, "totalCashPerShare": 6.737, "ebitda": -62934000, "totalDebt": 15488000, "quickRatio": 12.965, "currentRatio": 13.095, "debtToEquity": 9.384, "returnOnAssets": -0.32356, "returnOnEquity": -0.56723, "freeCashflow": -32367000, "operatingCashflow": -45927000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ANRO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "shortName": "Alto Neuroscience, Inc.", "postMarketChangePercent": 0.0, "postMarketPrice": 2.8, "postMarketChange": 0.0, "regularMarketChange": 0.02, "regularMarketDayRange": "2.67 - 2.817", "fullExchangeName": "NYSE", "averageDailyVolume3Month": 261633, "fiftyTwoWeekLowChange": 0.12999988, "fiftyTwoWeekLowChangePercent": 0.04868909, "fiftyTwoWeekRange": "2.67 - 18.35", "fiftyTwoWeekHighChange": -15.55, "fiftyTwoWeekHighChangePercent": -0.84741145, "fiftyTwoWeekChangePercent": -82.30426, "epsTrailingTwelveMonths": -2.38, "epsForward": -2.87, "fiftyDayAverageChange": -1.151, "fiftyDayAverageChangePercent": -0.29131866, "twoHundredDayAverageChange": -5.89065, "twoHundredDayAverageChangePercent": -0.67781466, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1706884200000, "postMarketTime": 1740776705, "regularMarketTime": 1740776402, "exchange": "NYQ", "messageBoardId": "finmb_1675972978", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketPrice": 2.8, "regularMarketChangePercent": 0.719424, "displayName": "Alto Neuroscience", "trailingPegRatio": null, "__fetch_time": "2025-03-01"}]